Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients

Antiviral Research

Volumn 111, Issue , 2014, Pages 53-59

  Van Der Ree, Meike H ^a   Van Der Meer, Adriaan J ^b   De Bruijne, Joep ^a   Maan, Raoel ^b   Van Vliet, Andre ^c   Welzel, Tania M ^d   Zeuzem, Stefan ^d   Lawitz, Eric J ^e   Rodriguez Torres, Maribel ^f   Kupcova, Viera ^g   Wiercinska Drapalo, Alcija ^h   Hodges, Michael R ⁱ   Janssen, Harry L A ^a,j   Reesink, Hendrik W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PRA Health Sciences   (Netherlands)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f Fundacion de Investigacion   (Spain)

^g UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ Santaris Pharma A/S   (United States)

^j TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

Anti miRNA treatment; C virus; Hepatitis; MicroRNA's miR 122

Indexed keywords

ALPHA2A INTERFERON; MICRORNA 122; MIRAVIRSEN; PEGINTERFERON; PLACEBO; RIBAVIRIN; ANTIVIRUS AGENT; MICRORNA; MIRN122 MICRORNA, HUMAN; OLIGONUCLEOTIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MALE; MIDDLE AGED; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; VIROLOGY; VIRUS REPLICATION;

HEPATITIS C VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84907484544     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.08.015     Document Type: Article

References (33)

1. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355 10.1038/nature02871
2. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.a. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin. Gastroenterol. Hepatol. 9 2011 10.1016/j.cgh.2011.03.004 509-516.e1
3. S. Bai, M.W. Nasser, B. Wang, S.-H. Hsu, J. Datta, H. Kutay, A. Yadav, G. Nuovo, P. Kumar, and K. Ghoshal MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib J. Biol. Chem. 284 2009 32015 32027 10.1074/jbc.M109.016774
4. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
5. V. Bihrer, M. Friedrich-Rust, B. Kronenberger, N. Forestier, J. Haupenthal, Y. Shi, J. Peveling-Oberhag, H.H. Radeke, C. Sarrazin, E. Herrmann, S. Zeuzem, O. Waidmann, and A. Piiper Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection Am. J. Gastroenterol. 106 2011 1663 1669 10.1038/ajg.2011.161
6. A.-C. Cardoso, R. Moucari, C. Figueiredo-Mendes, M.-P. Ripault, N. Giuily, C. Castelnau, N. Boyer, T. Asselah, M. Martinot-Peignoux, S. Maylin, R.J. Carvalho-Filho, D. Valla, P. Bedossa, and P. Marcellin Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J. Hepatol. 52 2010 652 657 10.1016/j.jhep.2009.12.028
7. L. Chen, I. Borozan, J. Feld, J. Sun, L.-L. Tannis, C. Coltescu, J. Heathcote, A.M. Edwards, and I.D. McGilvray Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 2005 1437 1444
8. C. Coulouarn, V.M. Factor, J.B. Andersen, M.E. Durkin, and S.S. Thorgeirsson Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties Oncogene 28 2009 3526 3536 10.1038/onc.2009.211
9. C. Esau, S. Davis, S.F. Murray, X.X. Yu, S.K. Pandey, M. Pear, L. Watts, S.L. Booten, M. Graham, R. McKay, A. Subramaniam, S. Propp, B.A. Lollo, S. Freier, C.F. Bennett, S. Bhanot, and B.P. Monia MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting Cell Metab. 3 2006 87 98 10.1016/j.cmet.2006.01.005
10. E. Estrabaud, M. Lapalus, P. Broët, K. Appourchaux, S. De Muynck, O. Lada, M. Martinot-Peignoux, I. Bièche, D. Valla, P. Bedossa, P. Marcellin, M. Vidaud, and T. Asselah Reduction of microRNA-122 expression in IFNL3 CT+TT carriers and during progression of fibrosis in patients with chronic hepatitis C J. Virol. 2014 10.1128/JVI.00016-14
11. R. Flisiak, J. Jaroszewicz, I. Flisiak, and T. Łapiński Update on alisporivir in treatment of viral hepatitis C Expert Opin. Investig. Drugs 21 2012 375 382 10.1517/13543784.2012.658641
12. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401 10.1038/nature08309
13. L.F.R. Gebert, M.a.E. Rebhan, S.E.M. Crivelli, R. Denzler, M. Stoffel, and J. Hall Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 Nucleic Acids Res. 42 2014 609 621 10.1093/nar/gkt852
14. B. Hajarizadeh, J. Grebely, and G.J. Dore Epidemiology and natural history of HCV infection Nat. Rev. Gastroenterol. Hepatol. 10 2013 553 562 10.1038/nrgastro.2013.107
15. M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat. Rev. Immunol. 13 2013 535 542 10.1038/nri3463
16. S. Hsu, B. Wang, J. Kota, J. Yu, S. Costinean, H. Kutay, L. Yu, S. Bai, K. La Perle, R.R. Chivukula, H. Mao, M. Wei, K.R. Clark, J.R. Mendell, M.A. Caligiuri, S.T. Jacob, J.T. Mendell, and K. Ghoshal Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver J. Clin. Invest. 122 2012 2871 2883 10.1172/JCI63539
17. H.L.A. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, K. Patel, A.J. van der Meer, A.K. Patick, A. Chen, Y. Zhou, R. Persson, B.D. King, S. Kauppinen, A.A. Levin, and M.R. Hodges Treatment of HCV infection by targeting microRNA N. Engl. J. Med. 368 2013 1685 1694 10.1056/NEJMoa1209026
18. C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581 10.1126/science.1113329
19. J. Krützfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, M. Manoharan, and M. Stoffel Silencing of microRNAs in vivo with "antagomirs" Nature 438 2005 685 689 10.1038/nature04303
20. M. Lagos-Quintana, R. Rauhut, A. Yalcin, J. Meyer, W. Lendeckel, and T. Tuschl Identification of tissue-specific microRNAs from mouse Curr. Biol. 12 2002 735 739
21. R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M.E. Munk, S. Kauppinen, and H. Orum Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201 10.1126/science.1178178
22. G.M. Lauer, and B.D. Walker Hepatitis C virus infection N. Engl. J. Med. 345 2001 41 52 10.1056/NEJM200107053450107
23. E.S. Machlin, P. Sarnow, and S.M. Sagan Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex Proc. Natl. Acad. Sci. U.S.A. 108 2011 3193 3198 10.1073/pnas.1012464108
24. R.T. Marquez, S. Bandyopadhyay, E.B. Wendlandt, K. Keck, B.A. Hoffer, M.S. Icardi, R.N. Christensen, W.N. Schmidt, and A.P. McCaffrey Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans Lab. Invest. 90 2010 1727 1736 10.1038/labinvest.2010.126
25. Y. Murakami, M. Tanaka, H. Toyoda, K. Hayashi, M. Kuroda, A. Tajima, and K. Shimotohno Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C BMC Med. Genomics 3 2010 48 10.1186/1755-8794-3-48
26. M. Sarasin-Filipowicz, J. Krol, I. Markiewicz, M.H. Heim, and W. Filipowicz Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy Nat. Med. 15 2009 31 33 10.1038/nm.1902
27. T.-H. Su, C.-H. Liu, C.-J. Liu, C.-L. Chen, T.-T. Ting, T.-C. Tseng, P.-J. Chen, J.-H. Kao, and D.-S. Chen Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C Proc. Natl. Acad. Sci. U.S.A. 110 2013 7844 7849 10.1073/pnas.1306138110
28. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, K.V. Shianna, T. Urban, N.H. Afdhal, I.M. Jacobson, R. Esteban, F. Poordad, E.J. Lawitz, J. McCone, M.L. Shiffman, G.W. Galler, W.M. Lee, R. Reindollar, J.W. King, P.Y. Kwo, R.H. Ghalib, B. Freilich, L.M. Nyberg, S. Zeuzem, T. Poynard, D.M. Vock, K.S. Pieper, K. Patel, H.L. Tillmann, S. Noviello, K. Koury, L.D. Pedicone, C.A. Brass, J.K. Albrecht, D.B. Goldstein, and J.G. McHutchison Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 10.1053/j.gastro.2010.04.013 120-129.e18
29. J. Trebicka, E. Anadol, N. Elfimova, I. Strack, M. Roggendorf, S. Viazov, I. Wedemeyer, U. Drebber, J. Rockstroh, T. Sauerbruch, H.-P. Dienes, and M. Odenthal Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis J. Hepatol. 58 2013 234 239 10.1016/j.jhep.2012.10.015
30. W.-C. Tsai, S.-D. Hsu, C.-S. Hsu, T.-C. Lai, S.-J. Chen, R. Shen, Y. Huang, H.-C. Chen, C.-H. Lee, T.-F. Tsai, M.-T. Hsu, J.-C. Wu, H.-D. Huang, M.-S. Shiao, M. Hsiao, and A.-P. Tsou MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis J. Clin. Invest. 122 2012 2884 2897 10.1172/JCI63455
31. A. Van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.-F. Dufour, F. Lammert, A. Duarte-Rojo, E.J. Heathcote, M.P. Manns, L. Kuske, S. Zeuzem, W.P. Hofmann, R.J. de Knegt, B.E. Hansen, and H.L.A. Janssen Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593 10.1001/jama.2012.144878
32. A.J. Van der Meer, W.R.R. Farid, M.J. Sonneveld, P.E. de Ruiter, A. Boonstra, A.J. van Vuuren, J. Verheij, B.E. Hansen, R.J. de Knegt, L.J.W. van der Laan, and H.L.A. Janssen Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122 J. Viral Hepat. 20 2013 158 166 10.1111/jvh.12001
33. O. Waidmann, V. Bihrer, B. Kronenberger, S. Zeuzem, A. Piiper, and N. Forestier Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection Dig. Liver Dis. 44 2012 438 441 10.1016/j.dld.2011.11.011